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INTRODUCTION 
 
 The active ingredient of the recreational drug 
ecstasy, 3,4-methylenedioxy-methamphetamine 
(MDMA), is a ring-substituted amphetamine derivative. 
Following its entry into the central nervous system 
MDMA can bind the serotonin (5-HT), dopamine (DA) 
and noradrenaline (NA) transporters (SERT, DAT, NAT, 
respectively). After the binding MDMA is transported 
into the cells via these proteins and its uptake is 
paralleled by the release of the mentioned monoamines. 
The released 5-HT, DA and NA are responsible for the 
acute positive effects of ecstasy, like euphoria, 
tirelessness, and the so called entactogenic effect, which 
means an elevated sociability. At the same time, MDMA 
also initiates processes able to impair the neurons 
acutely, e.g. hyperthermia, free radical production and 
impairment of the cerebral autoregulation, thereby the 
elevated neuronal demand for glucose and oxygen will be 
accompanied with vasoconstriction. On the long-run 
MDMA causes a decrease in serotonergic markers, which 
is interpreted as a selective serotonergic toxicity. The 
levels of tryptophan-hydroxylase or SERT is decreased in 
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brain regions, where 5-HT containing neurons, 
originating in the raphe nuclei, project. Parallel to the 
alterations within the serotonergic system, functional 
impairments also occur, and in users elevated depression, 
disturbed cognitive and motor functions can be observed. 
Through animal experiments in recent years, changes in 
the serotonergic system became partially delineated, 
however, the non-specific neurotoxic mechanisms raise 
the possibility of other alterations underlying the 
MDMA-induced chronic, functional impairments. 
 Venlafaxine (VLX) is a therapeutically effective 
antidepressant on the market, which through binding to 
SERT and NAT can elevate 5-HT and NA levels, but to a 
lesser extent than MDMA. Most of the antidepressants 
can also bind acutely to these transport proteins. 
However, acute elevations in monoamine concentrations 
cannot be exclusively responsible for the therapeutic 
effects, because 1) antidepressant efficacy is first visible 
after weeks, 2) approximately 30-40% of patients are 
resistant to current antidepressant therapies, 3) 
combination with psychotherapy was more effective than 
pharmacological treatments alone. Several theories tried 
to explain these discrepancies. One of them suggested 
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chronically elevated monoamine levels through the 
desensitization of 5-HT1B, 5- , 
while another, the so called synaptic theory of 
depression, stated that in depression the number of 
synapses may be substantially decreased and 
antidepressants may reinstate impaired network functions 
through the induction of synapse formation. While 
alterations in depression and subsequent antidepressant 
treatments in the so called depression circuitry, the 
prefrontal cortex, hippocampus and amygdala, were 
evaluated by multiple experiments, studies in other brain 
regions, like the frontal cortex, which has dense 
serotonergic innervations and a confirmed role in 
depression, are scarce. Furthermore, the synaptic theory 
of depression raises the possibility of the use of 
antidepressants in other pathological states, e.g. stroke, 
where cortical regions also play a role. Indeed, 
fluoxetine, a selective 5-HT reuptake inhibitor showed 
efficacy in a clinical study evaluating motor recovery 
following stroke and VLX activated motor cortices of 
healthy individuals in another experiment. It remains 
unclear, however, what molecular changes can be 
responsible for the therapeutic actions of VLX, which 
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possess an extended mechanism of action via the 
inhibition of both 5-HT and NA reuptake, since these 
alterations are unevaluated at therapeutically relevant 
time points in the frontal cortex.  
In the light of the above, the two substances, 
MDMA and VLX, can both acutely, through alterations 
of monoaminergic levels, and chronically influence each 
consequences, like motor 
and cognitive disturbances and depression in MDMA 
users and elevated motor and cognitive functioning and 
antidepressant effects after chronic VLX administration 
also raise the possibility of interactions. Furthermore, in 
an experiment previous MDMA administration 
attenuated the effects of chronic fluoxetine. However, 
according to our knowledge, effects of chronic VLX 
administration following acute MDMA administration 
remained unevaluated.  
 
OBJECTIVES 
 
1. Evaluation of the molecular mechanisms three 
weeks after a single dose MDMA administration, 
which may play a part in functional impairments 
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or a possible regeneration in the frontal cortical 
regions.  
2. Discovery of signaling pathways, which may 
underlie the therapeutic effects of VLX after a 3-
weeks long chronic treatment in the frontal 
cortex.  
3. To examine, if and how 3-weeks long VLX 
treatment may influence the MDMA-caused 
alterations, and whether a previous MDMA 
administration may have impact on the changes 
induced by VLX in frontal cortical regions.  
 
METHODS 
 
 We used 42, eight weeks old Dark Agouti rats. 
These animals possess an enzyme polymorphism, which 
results in a slower metabolism rate of MDMA, and thus, 
represent the human population which may be especially 
vulnerable to neurotoxic effects of the drug. The animals 
were divided in two groups and received single saline 
injections (SAL) or MDMA (15 mg/kg) intraperitoneally. 
Thereafter two further subgroups were made, one of them 
received three weeks long VLX treatment (40 mg/kg via 
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minipumps), while the control group contained animals 
with sham operations or saline containing minipumps 
(SHAM). This protocol resulted in four treatment groups: 
control animals (SAL/SHAM), MDMA treated- 
(MDMA/SHAM) and VLX treated animals (SAL/VLX), 
and those receiving a combined treatment 
(MDMA/VLX). 
 After three weeks animals were decapitated, 
frontal cortical regions dissected and RNA extracted with 
TRIZOL method. The samples were exposed to quality 
measurements and 2-2 samples from the eight samples 
with the best values were pooled. 
 The 4 pooled samples per treatment group were 
examined with whole-genome expression microarrays 
(Illumina RatRef-12 v1) containing 22 523 different 
probes.  
 Raw data were background corrected and 
normalized using program packages for R statistical 
programing language. Thereafter, significantly altered 
genes were determined by the PUMA package, while to 
avoid bias from multiple hypothesis testing, significance 
criteria were reduced. We identified significantly altered 
biological pathways with gene set enrichment analysis 
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(GSEA). To reveal interactions ANOVA was also 
performed.  
 
RESULTS 
 
 In the MDMA treated group, following the 
grouping of the enriched gene sets into biological 
pathways, protein synthesis and -localization, 
transmembrane- and nucleocytoplasmic transport, 
chromatin maintenance and mitochondrial 
oxidoreductase activity related gene sets were found to 
be downregulated, while gene sets of dendrite- and 
synapse development showed elevated expression 3 
weeks after a single-dose treatment in the frontal cortex. 
Individual genes supported the findings: downregulations 
were evident in genes of some ribosomal proteins, while 
calcium/calmodulin-dependent kinases and the 
NMDA2B type glutamate transporter showed elevated 
expressions, among others.  
 In the case of the VLX, significantly enriched 
gene sets could be grouped to four main biological 
processes. Gene sets implicated in neurotransmitter 
release, synaptic plasticity and -organization, and 
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insulinergic signaling were upregulated, while those 
involved in mitochondrial antioxidant activity were 
downregulated. On the gene level, insulinergic (Dpp4) 
and glutamatergic (Grin2b, Gria) genes and 
calcium/calmodulin dependent kinases showed elevated 
expression, while those related to mitochondrial activity 
were downregulated. The galaninergic genes remained 
unaltered. 
 Comparison of the double treated group to the 
VLX treated animals showed that the expression of gene 
sets involved in biosynthetic processes and mitochondrial 
functions was decreased, while Stat3 signaling was 
upregulated. Comparison of the combination treatment to 
the MDMA treated animals revealed that gene sets 
related to the ribosomal subunits and translation showed 
underexpression, but some genes with known 
antidepressant activity (Ca2, Rgs9) were upregulated. 
 The combined treatment compared to the control 
group showed elevations in the expression of gene sets 
related to neurotransmitter release, synaptic plasticity, 
insulinergic- and glutamatergic signaling and a 
downregulation of mitochondrial functions, translation 
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and other biosynthetic processes, pointing out to possible 
additive effects of the two substances.  
 The ANOVA analysis demonstrated interaction 
effects only in case of TATA-box binding protein, 
confirming that the other changes are additive effects.  
 
CONCLUSIONS  
 
1. MDMA may cause functional deficits via the 
downregulation of biosynthetic processes and 
decreased mitochondrial antioxidant activity, 
however, 3 weeks after its administration growth 
of dendrite trees may mark ongoing recovery 
processes in the frontal cortical region. 
2. Gene sets related to neurotransmitter release after 
3-weeks long, chronic VLX administration 
suggest adaptive mechanisms, while 
upregulations of synaptic connectivity related 
gene sets support the synaptic theory behind its 
antidepressant effects. We identified insulinergic 
pathway as a so far undiscovered mechanism of 
action. VLX also attenuated mitochondrial 
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antioxidant activities and could not influence the 
expression of galanin genes.  
3. In the combined treatment, we can conclude, that 
most of the effects are additive except TATA-box 
binding protein, which may be implicated in the 
regulation of mitochondrial and translational 
processes. The MDMA administration three 
weeks earlier could not influence the effects of 
chronic VLX treatment and similarly, VLX could 
not reverse the changes induced by MDMA. At 
the same time, the antidepressant could exert its 
wide-scale positive upregulations probably also 
involved in its therapeutic effects, which raises 
the possibility of its use in cortical diseases even 
in previous addicts.  
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